Sabby Management’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Sabby Management’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,791	Closed	-$542K	–	116
2023 Q2	$542K	Buy	11,791 +11,080	+1,558%	+$2.24M	0.44%	25
2023 Q1	$189K	Buy	+711	New	+$689K	0.16%	46

Other funds holding PBLA

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Sabby Management's PBLA Position: Q3 2023 in Review

Sabby Management sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q3 2023, closing a stake of 11,791 shares — an estimated $542K sold.

Sabby Management first reported a position in PBLA in Q1 2023 and held it in 2 quarters. The position peaked at $542K in Q2 2023. 5 funds tracked by Wall St. Rank hold PBLA as of Q3 2023.

Sabby Management reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Sabby Management sold 11,791 Panbela Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $542K.
Sabby Management first reported a position in Panbela Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
Sabby Management's Panbela Therapeutics, Inc. Common Stock position peaked at $542K in Q2 2023.
5 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Sabby Management's 13F filing for Q3 2023, filed 14 Nov 2023.